Chunk #34 — 2. Inhibitors of the NF-κB activation pathway — 2.8. Other mechanisms of NF-κB inhibition — 2.8.5. p53 induction

Source

Inhibiting NF-κB activation by small molecules as a therapeutic strategy.

Embedded

yes

Text

and NF-κB pathways. Quinacrine, an antimalarial drug, and other derivatives of 9 aminoacridine have been shown to simultaneously repress NF-κB and activate p53 in renal cell carcinoma [192]. Other molecules with similar potential include nutlins [193, 194], cisplatin [195, 196], leptomycin B [197, 198], adenosine-2,3-dialdehyde [199], the NSAID JTE-522 [200], and the cyclin-dependent kinase inhibitors R-roscovitine [201, 202]; and flavopiridol [203, 204].